These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 23838105)

  • 1. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.
    Naci H; Brugts J; Ades T
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):390-9. PubMed ID: 23838105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials.
    Naci H; Brugts JJ; Fleurence R; Ades AE
    Eur J Prev Cardiol; 2013 Aug; 20(4):658-70. PubMed ID: 23529608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials.
    Naci H; Brugts JJ; Fleurence R; Tsoi B; Toor H; Ades AE
    Eur J Prev Cardiol; 2013 Aug; 20(4):641-57. PubMed ID: 23447425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
    Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
    Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.
    Zhang X; Xing L; Jia X; Pang X; Xiang Q; Zhao X; Ma L; Liu Z; Hu K; Wang Z; Cui Y
    Cardiovasc Ther; 2020; 2020():3987065. PubMed ID: 32411300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.
    Alberton M; Wu P; Druyts E; Briel M; Mills EJ
    QJM; 2012 Feb; 105(2):145-57. PubMed ID: 21920996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
    Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin-related adverse events: a meta-analysis.
    Silva MA; Swanson AC; Gandhi PJ; Tataronis GR
    Clin Ther; 2006 Jan; 28(1):26-35. PubMed ID: 16490577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis.
    Delahoy PJ; Magliano DJ; Webb K; Grobler M; Liew D
    Clin Ther; 2009 Feb; 31(2):236-44. PubMed ID: 19302897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of incident diabetes among patients treated with statins: population based study.
    Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
    BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
    Karlson BW; Barter PJ; Palmer MK; Lundman P; Nicholls SJ
    Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):697-703. PubMed ID: 22705128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.
    Cui JY; Zhou RR; Han S; Wang TS; Wang LQ; Xie XH
    J Clin Pharm Ther; 2018 Aug; 43(4):556-570. PubMed ID: 29733433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
    Geng Q; Ren J; Chen H; Lee C; Liang W
    Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses.
    Cai T; Abel L; Langford O; Monaghan G; Aronson JK; Stevens RJ; Lay-Flurrie S; Koshiaris C; McManus RJ; Hobbs FDR; Sheppard JP
    BMJ; 2021 Jul; 374():n1537. PubMed ID: 34261627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
    Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
    Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.